TP53 and Let-7a micro-RNA Regulate K-Ras Activity in HCT116 Colorectal Cancer Cells

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Luu, Carrie ^a   Heinrich, Eileen L ^a   Duldulao, Marjun ^a   Arrington, Amanda K ^a   Fakih, Marwan ^a   Garcia Aguilar, Julio ^b   Kim, Joseph ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; K RAS PROTEIN; LETHAL 7A MICRORNA; MESSENGER RNA; MICRORNA; PROTEIN P53; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CANCER SURVIVAL; CHEMORADIOTHERAPY; COLORECTAL CANCER; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE INTERACTION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; ONCOGENE K RAS; PROTEIN FUNCTION; REGULATORY MECHANISM; SENSITIVITY ANALYSIS; TUMOR SUPPRESSOR GENE;

ALLELES; CHEMORADIOTHERAPY; COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HUMANS; MICRORNAS; MUTATION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84880988462     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070604     Document Type: Article

References (34)

1. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, et al. (2012) Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 62: 220-241.
2. Bell SM, Scott N, Cross D, Sagar P, Lewis FA, et al. (1993) Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology 104: 57-64.
3. Lumachi F, Orlando R, Marino F, Chiara GB, Basso SM, (2012) Expression of p53 and Ki-67 as prognostic factors for survival of men with colorectal cancer. Anticancer Res 32: 3965-3967.
4. Umeda Y, Nagasaka T, Mori Y, Sadamori H, Sun DS, et al. (2013) Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability. J Hepatobiliary Pancreat Sci 20: 223-233.
5. Tie J, Lipton L, Desai J, Gibbs P, Jorissen RN, et al. (2011) KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer. Clin Cancer Res 17: 1122-1130.
6. De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, et al. (2008) KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 19: 508-515.
7. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, et al. (1988) Genetic alterations during colorectal-tumor development. N Engl J Med 319: 525-532.
8. Russo A, Bazan V, Lacopetta B, Kerr D, Soussi T, et al. (2005) The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol 23: 7518-7528.
9. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, et al. (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66: 3992-3995.
10. Garcia-Aguilar J, Chen Z, Smith DD, Li W, Madoff RD, et al. (2011) Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer. Ann Surg 254: 486-492.
11. Smith G, Carey FA, Beattie J, Wilkie MJV, Lightfoot TJ, et al. (2002) Mutations in APC, Kirsten-ras, and p53-alternative genetic pathways to colorectal cancer. Proc Natl Acad Sci USA 99: 9433-9438.
12. Tortola S, Marcuello E, González I, Reyes G, Arribas R, et al. (1999) p53 and K-ras gene mutations correlate with tumor aggressiveness but are not of routine prognostic value in colorectal cancer. J Clin Oncol 17: 1375-1375.
13. Zhang B, Pan X, Cobb GP, Anderson TA, (2007) microRNAs as oncogenes and tumor suppressors. Dev Biol 302: 1-12.
14. Filipowicz W, Bhattacharyya SN, Sonenberg N, (2008) Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 9: 102-114.
15. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, et al. (2005) RAS is regulated by the let-7 microRNA family. Cell 120: 635-647.
16. He X, Chen J, Zhang Z, Li C, Peng Q, et al. (2010) The let-7a microRNA protects from growth of lung carcinoma by suppression of k-Ras and c-Myc in nude mice. J Cancer Res Clin Oncol 136: 1023-1028.
17. Ruzzo A, Graziano F, Vincenzi B, Canestrari E, Perrone G, et al. (2012) High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease. Oncologist 17: 823-829.
18. Saleh AD, Savage JE, Cao L, Soule BP, Ly D, et al. (2011) Cellular stress induced alterations in microRNA let-7a and let-7b expression are dependent on p53. PLoS One 6: e24429.
19. Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, et al. (2007) p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol 17: 1298-1307.
20. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, et al. (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282: 1497-1501.
21. Rivlin N, Brosh R, Oren M, Rotter V, (2011) Mutations in the p53 tumor suppressor gene: Important milestones at the various steps of tumorigenesis. Genes Cancer 2: 466-474.
22. Spitzner M, Emons G, Kramer F, Gaedcke J, Rave-Fränk M, et al. (2010) A gene expression signature for chemoradiosensitivity of colorectal cancer cells. Int J Radiat Oncol Biol Phys 78: 1184-1192.
23. Bazan V, Migliavacca M, Zanna I, Tubiolo C, Grassi N, et al. (2002) Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. Ann Oncol 13: 1438-1446.
24. Johnson CD, Esquela-Kerscher A, Stefani G, Byrom M, Kelnar K, et al. (2007) The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res 67: 7713-7722.
25. Akao Y, Nakagawa Y, Naoe T, (2006) let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biol Pharm Bull 29: 903-906.
26. He L, He X, Lowe SW, Hannon GJ, (2007) microRNAs join the p53 network-another piece in the tumour-suppression puzzle. Nat Rev Cancer 7: 819-822.
27. Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, et al. (2007) Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 26: 731-743.
28. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, et al. (1999) Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 104: 263-270.
29. Tazawa H, Tsuchiya N, Izumiya M, Nakagama H, (2007) Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci USA 104: 15472-15477.
30. Han Z, Yang Q, Liu B, Wu J, Li Y, et al. (2012) MicroRNA-622 functions as a tumor suppressor by targeting K-Ras and enhancing the anticarcinogenic effect of resveratrol. Carcinogenesis 33: 131-139.
31. Levy R, Biran A, Poirier F, Raz A, (2011) Kloog (2011) Y Galectin-3 mediates cross-talk between K-Ras and Let-7c tumor suppressor microRNA. PLoS One 6: e27490.
32. Ji B, Tsou L, Wang H, Gaiser S, Chang DZ, et al. (2009) Ras activity levels control the development of pancreatic diseases. Gastroenterology 137: 1072-1082.e6.
33. García-Aguilar J, Hernandez de Anda E, Sirivongs P, Lee S-H, Madoff R, et al. (2003) A pathologic complete response to preoperative chemoradiation is associated with lower local recurrence and improved survival in rectal cancer patients treated by mesorectal excision. Dis Colon Rectum 46: 298-304.
34. Janjan NA, Crane C, Feig BW, Cleary K, Dubrow R, et al. (2001) Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer. Am J Clin Oncol 24: 107-112.